Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the action to control cardiovascular risk in diabetes study)

American Journal of Cardiology

Volumn 114, Issue 8, 2014, Pages 1217-1222

  Fatemi, Omid ^a,b,c   Yuriditsky, Eugene ^a,b,c   Tsioufis, Costas ^d   Tsachris, Demetrios ^d   Morgan, Timothy ^e   Basile, Jan ^f,g   Bigger, Thomas ^h   Cushman, William ⁱ   Goff, David ^j   Soliman, Elsayed Z ^e   Thomas, Abraham ^k   Papademetriou, Vasilios ^b,c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^c Washington DC Cancer Registry   (United States)

^d UNIVERSITY OF ATHENS   (Greece)

^e WAKE FOREST BAPTIST HEALTH   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^h NewYork Presbyterian Hospital   (United States)

ⁱ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^j Global Health and Health Disparities   (United States)

^k HENRY FORD HEALTH SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ATRIAL FIBRILLATION; BLOOD; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; INCIDENCE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; PREVALENCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE; TRENDS; UNITED STATES;

ADULT; AGED; ATRIAL FIBRILLATION; BLOOD GLUCOSE; CANADA; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 84921726558     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.07.045     Document Type: Article

References (27)

1. Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in highrisk hypertension (from the VALUE trial). Am J Cardiol 2008;101:634-638.
2. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-844.
3. Dublin S, Glazer NL, Smith NL, Psaty DM, Lumley T, Wiggins KL, Page RL, Heckbert SR. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med 2010;25:853-858.
4. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011;108:56-62.
5. Huxley RR, Alonso A, Lopez FL, Filion KB, Agarwal LR, Soliman EZ, Pankow JS, Selvin E. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart 2012;98:133-138.
6. Lin Y, Li H, Lan X, Chen X, Zhang A, Li Z. Mechanisms of and therapeutic strategy for atrial fibrillation. Sci World J 2013;2013: http://dx.doi.org/10.1155/2013/209428.
7. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005;105:315-318.
8. Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of atrial fibrillation in women. J Am Coll Cardiol 2012;60:1421-1428.
9. Du A, Ninomiya T, deGalan B. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009;30:1128-1135.
10. Haga KK, McClymont KL, Clarke S, Grounds RS, Ng KY, Glyde DW, Loveless RJ, Carter GH, Alston RP. The effects of tight glycemic control, during and after cardiac surgery, on patient mortality and morbidity: a systematic review and meta-analysis. J Cardiothorac Surg 2011;6:3.
11. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004;109:1497-1502.
12. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RJ Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
13. Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Feinglos MN, Kirk JK, Hamilton BP, Ismail-Beigi F, Feeney P. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:34i-43i.
14. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedwald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:21i-33i.
15. Prineas RJ, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification. Boston, Massachusetts: John Wright - PSG, Inc., 1982:330.
16. Nichols GA, Reinier K, Chugh SS. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 2009;23:1851-1856.
17. Herringa J, va der Kuip DAM, Hofman A, kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-953.
18. Magnani JW, Rienstra M, Lin H, Sinner MF, Lubitz SA, McManus DD, Dupuis J, Ellinor PT, Benjamin EJ. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation 2011;124:1982-1993.
19. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, Benjamin EJ. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-2477.
20. Kato T, Yamashita T, Sekiguchi A, Tsuneda T, Sagara K, Takamura M, Kaneko S, Aizawa T, Fu LT. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol 2008;19:415-420.
21. Wakili R, Voigt N, Kaab S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest 2011;121:2955-2968.
22. Sun Y, Hu D. The link between diabetes and atrial fibrillation: cause or correlation? J Cardiovasc Dis Res 2010;1:10-11.
23. Frier BM, Schernthaner G, Heller S. Hypoglycemia and cardiovascular risks. Diabetes Care 2011;34:S132-S137.
24. Wright RJ, Newby DE, Sirling D, Ludlam CA, Mcdonald IA, Frier BM. Effects of acute insulin-induced hypoglycemic on indices of inflammation: putative mechanisms of aggravating vascular disease in diabetics. Diabetes Care 2010;33:1591-1597.
25. Ozaydin M. Atrial fibrillation and inflammation. World J Cardiol 2010;2:243-250.
26. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2010;60:2263-2270.
27. Jhanjee R, Templeton GA, Sattiraju S, Nguyen J, Sakaguchi S, Lu F, Ermis C, Milstein S, Van Heel L, Lurie KG, Benditt DG. Relationship of paroxysmal atrial tachyarrhythmias to volume overload. Circ Arrhythm Electrophysiol 2009;2:488-494.